Skip to search formSkip to main contentSkip to account menu

GIMEMA ALL 0394

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Bortezomib-melphalan-prednisone (VMP) and continuous lenalidomide-dexamethasone (Rd) represent the standard treatment of… 
2019
2019
Most patients affected by Myelodysplastic syndromes (MDS) develop transfusion dependence, which can be correlated with poorer… 
2018
2018
Introduction: The phase 3 GIMEMA-MMY-3006 trial comparing bortezomib-thalidomide-dexamethasone (VTD) versus thalidomide… 
Review
2017
Review
2017
Multiple myeloma (MM) is the second most frequent hematological neoplasia, characterized by the accumulation of malignant plasma… 
2015
2015
Introduction The introduction of novel agents in the treatment of Multiple Myeloma (MM) led to a significant improvement in the… 
2014
2014
Substantial efficacy has been demonstrated with bortezomib-melphalan-prednisone in phase III studies in transplant-ineligible… 
2014
2014
Multiple myeloma is a plasma cell disorder characterized by malignant plasma cell infiltration in the bone marrow, serum and/or… 
2014
2014
Multiple Myeloma is a plasma cell disorder, characterized by malignant plasma cell infiltration in the bone marrow, serum and/or… 
2013
2013
Chaperot, L., Bendriss, N., Manches, O., Gressin, R., Maynadie, M., Trimoreau, F., Orfeuvre, H., Corront, B., Feuillard, J… 
Highly Cited
2005
Highly Cited
2005
The role of all-trans retinoic acid (ATRA) in pediatric acute promyelocytic leukemia (APL) is the topic of several ongoing…